Standard of Care Treatment for Patients with Advanced RAI-R-DTC

Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Health-related, mental, and emotional quality of life often suffer when patients with thyroid cancer undergo thyroidectomy. However, research shows it may be only in the short-term.

In an interview with Targeted Oncology, Francis P. Worden, MD, shed light on the evolving landscape of advanced thyroid cancer treatment, offering valuable insights into the available options.

Results from a retrospective study found that patients with certain features were at a greater risk of recurrence of papillary thyroid cancer.